INSM
INSMED Inc
NASDAQ · Healthcare · Biotechnology · US
$110.00
+5.32%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$106.85
From 52W high−47.97%
Volume4.94M
Market cap$24.13B
P/E (TTM)—
P/S (TTM)15.9x
Div yield—
Key dataNov 4, 2026
Open
$106.85
From 52W high
−47.97%
Volume
4.94M
Market cap
$24.13B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−48.0x
P/E (TTM)
—
RSI (14)
52.3
MomentumView details →
1D Return
+5.32%
YTD Return
−39.03%
SummaryUpdated Sep 1, 2026
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey. The company has evolved from its early days to become a specialized developer and commercializer of therapies for patients with serious and rare diseases, particularly focusing on respiratory conditions. Insmed went public in 2000 and has built its business around innovative drug delivery technologies and treatments for orphan diseases with significant unmet medical needs.
Similar companies
Latest newsMore news →
INSMED Inc shares rallied 15%.6d agoINSMED Inc reported a third-quarter loss of $0.46 per share, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.34 loss and a $1.75 loss per share a year earlier.7d agoInsmed raised its 2026 revenue guidance to $1.35 billion–$1.4 billion for BRINSUPRI and $460 million–$470 million for ARIKAYCE.7d ago